Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
- PMID: 9261346
- PMCID: PMC191902
- DOI: 10.1128/JVI.71.9.6296-6304.1997
Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
Abstract
Several members of the chemokine receptor family have recently been identified as coreceptors, with CD4, for entry of human immunodeficiency virus type 1 (HIV-1) into target cells. In this report, we show that the envelope glycoproteins of several strains of HIV-2 and simian immunodeficiency virus (SIV) employ the same chemokine receptors for infection. Envelope glycoproteins from HIV-2 use CCR5 or CXCR4, while those from several strains of SIV use CCR5. Our data indicate also that some viral envelopes can use more than one coreceptor for entry and suggest that some of these coreceptors remain to be identified. To further understand how different envelope molecules use CCR5 as an entry cofactor, we show that soluble purified envelope glycoproteins (SU component) from CCR5-tropic HIV-1, HIV-2, and SIV can compete for binding of iodinated chemokine to CCR5. The competition is dependent on binding of the SU glycoprotein to cell surface CD4 and implies a direct interaction between envelope glycoproteins and CCR5. This interaction is specific since it is not observed with SU glycoprotein from a CXCR4-tropic virus or with a chemokine receptor that is not competent for viral entry (CCR1). For HIV-1, the interaction can be inhibited by antibodies specific for the V3 loop of SU. Soluble CD4 was found to potentiate binding of the HIV-2 ST and SIVmac239 envelope glycoproteins to CCR5, suggesting that a CD4-induced conformational change in SU is required for subsequent binding to CCR5. These data suggest a common fundamental mechanism by which structurally diverse HIV-1, HIV-2, and SIV envelope glycoproteins interact with CD4 and CCR5 to mediate viral entry.
Similar articles
-
Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins.Virology. 1998 Sep 30;249(2):367-78. doi: 10.1006/viro.1998.9306. Virology. 1998. PMID: 9791028
-
Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.J Virol. 2002 Nov;76(21):10627-36. doi: 10.1128/jvi.76.21.10627-10636.2002. J Virol. 2002. PMID: 12368305 Free PMC article.
-
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.J Virol. 1997 Dec;71(12):8999-9007. doi: 10.1128/JVI.71.12.8999-9007.1997. J Virol. 1997. PMID: 9371556 Free PMC article.
-
[Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].Acta Med Port. 2008 Sep-Oct;21(5):497-504. Epub 2009 Jan 16. Acta Med Port. 2008. PMID: 19187693 Review. Portuguese.
-
Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors.Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):219-43. doi: 10.1016/s1359-6101(00)00033-2. Cytokine Growth Factor Rev. 2001. PMID: 11325604 Review.
Cited by
-
Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.Antimicrob Agents Chemother. 2001 Mar;45(3):664-72. doi: 10.1128/AAC.45.3.664-672.2001. Antimicrob Agents Chemother. 2001. PMID: 11181340 Free PMC article.
-
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11013-8. doi: 10.1073/pnas.1832214100. Epub 2003 Aug 20. Proc Natl Acad Sci U S A. 2003. PMID: 12930892 Free PMC article.
-
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.J Virol. 2009 Jul;83(14):7099-108. doi: 10.1128/JVI.02522-08. Epub 2009 May 6. J Virol. 2009. PMID: 19420078 Free PMC article.
-
Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)).J Virol. 2001 Oct;75(19):9328-38. doi: 10.1128/JVI.75.19.9328-9338.2001. J Virol. 2001. PMID: 11533196 Free PMC article.
-
Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.J Virol. 2000 Sep;74(17):7922-35. doi: 10.1128/jvi.74.17.7922-7935.2000. J Virol. 2000. PMID: 10933700 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials